London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Updated on Hemo Twitter as well about recent progress and implied fair value of £90m based on an evaluation of the company's peers.
Hemogenyx Pharmaceuticals (HEMO.L*): Update Note - 21 May 2024
Entering the clinic with HEMO-CAR-T
· Clinical hold lifted for HEMO-CAR-T: The US Food and Drug Administration (FDA) has consented to Hemogenyx proceeding with its Phase I clinical study of HEMO-CAR-T.
HEMO-CAR-T Phase 1 trial set to begin this year: Hemogenyx is planning a Phase 1/2 trial using HEMO-CAR-T in patients with relapsed or refractory (r/r) Acute Myeloid Leukaemia (AML). The study should generate safety data and provide a preliminary indication of efficacy.
Fundraise supporting the initiation of the clinical trial: Earlier this year, the Company completed a placing to raise $4m to support clinical development of HEMO-CAR-T.
Cell therapies remain an area of industry interest: There continue to be a number of transactions concerning cell therapy assets at an early clinical stage. The generation of clinical data on HEMO-CAR-T should support potential partnership discussions.
Continued progress on CBR: Researchers at the Company have identified a protein which could be used to develop an off-the-shelf therapy with activity against a wide range of viral diseases. Should CBR generate positive data, we expect interest from biodefence programmes
Implied fair value of £90m based on an evaluation of the Company’s peers.
HEMO need to update regarding partnership with big pharma and biodefence programme as well to make sure that they are genuinely working on that part and hope to get that update soon.
It's just an attempt to support /pump the sp. Nothing concrete as usual.
Love that the most liked post of today is Sccsss being called an idiot. Must be hard posting on here when everyone thinks you're a fool. You could even have something useful to say but your post history and childish responses had led to everyone disregarding everything you have to say. Sad times for Sccsss.
I'm glad I'm keeping you entertained :)
You all know deep down what the score is.
Cool, some positivity for hemo with that note. Fair value is £90 mil. Current mc is just under 20 so 90 mil is 6.75p. Tasty.
Begs the question why could/did they only raise at 2p (with circa 50% discount)?
Afternoon all invested
Last few weeks May well have been a rough passage of market play for investors in thin vol ,
However ..
If you thought it was worth 2p as per the placement & a lot higher for Prevail , then surely 1.5 is a gift / dry powder .
The stock will move fast north on the right news / update imo
& plenty topping up today -however the stock requires news & volume
I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail .
Noted by Prevail in Sept RNS 👍
Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."
Also as per Subush post earlier - Twitter update very positive on Hemo
Let’s see what next few months bring in the beautiful summer sunshine 👍
Is that because Vlad wanted to keep 100% of his company and who wouldn't keep up the great work Vlad and team 👏. Dare we say the churn has finished?
Side note my 8 year old has had his tumour removed and margin around still early days. I hope one day Vlads work will greatly benefit all especially children 🙏 x
Best wishes for a full recovery for your son BigBone.
Second that, good luck